Shield Therapeutics (LON:STX) Sets New 52-Week High – Here’s What Happened

Shares of Shield Therapeutics plc (LON:STX) reached a new 52-week high during trading on Wednesday . The stock traded as high as GBX 9.40 and last traded at GBX 9.10, with a volume of 13717261 shares. The stock had previously closed at GBX 8.40.

Analyst Ratings Changes

Separately, Peel Hunt reiterated a “buy” rating and set a GBX 15 price objective on shares of Shield Therapeutics in a report on Friday, November 7th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of GBX 15.

Shield Therapeutics Stock Performance

The firm has a 50 day moving average price of GBX 7.34 and a 200 day moving average price of GBX 5.35. The stock has a market cap of £96.62 million, a PE ratio of -4.55 and a beta of 1.42. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.